يعرض 1 - 10 نتائج من 60 نتيجة بحث عن '"КОРОНОВИРУСНАЯ ИНФЕКЦИЯ"', وقت الاستعلام: 0.72s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المصدر: Сборник статей

    وصف الملف: application/pdf

    العلاقة: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей VIII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 19-20 апреля 2023 г.; Евдокимова, Д. Г. Энтеровирусный менингит на фоне новой коронавирусной инфекции у детей / Д. Г. Евдокимова, Ю. Б. Хаманова, А. О. Овчинникова. - Текст электронный. // Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей VIII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 19-20 апреля 2023 г. – Екатеринбург : УГМУ, 2023. – C. 1360-1365.; http://elib.usma.ru/handle/usma/13963Test

  2. 2
    دورية أكاديمية

    المصدر: The Siberian Journal of Clinical and Experimental Medicine; Том 37, № 4 (2022); 63-69 ; Сибирский журнал клинической и экспериментальной медицины; Том 37, № 4 (2022); 63-69 ; 2713-265X ; 2713-2927

    وصف الملف: application/pdf

    العلاقة: https://www.sibjcem.ru/jour/article/view/1621/759Test; Beyerstedt S., Casaro E.B., Rangel É.B. COVID-19: Angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARSCoV-2 infection. Eur. J. Clin. Microbiol. Infect. Dis. 2021;40(5):905–919. DOI:10.1007/s10096-020-04138-6.; Azkur A.K., Akdis M., Azkur D., Sokolowska M., van de Veen W., Brüggen M.C. et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75(7):1564– 1581. DOI:10.1111/all.14364.; Feng Y., Ling Y., Bai T., Xie Y., Huang J., Li J. et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am. J. Respir. Crit. Care Med. 2020;201(11):1380–1388. DOI:10.1164/rccm.202002-0445OC.; Kalyanaraman Marcello R., Dolle J., Grami S., Adule R., Li Z., Tatem K. et al. Characteristics and outcomes of COVID-19 patients in New York City’s public hospital system. PLoS One. 2020;15(12):e0243027. DOI:10.1371/journal.pone.0243027.; Guan W.J., Ni Z.Y., Hu Y., Yu Q., Liu W., Pu J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382(18):1708–1720. DOI:10.1056/NEJMoa2002032.; Gerayeli F.V., Milne S., Cheung C., Li X., Yang C.W.T., Tam A. et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2021;33:100789. DOI:10.1016/j.eclinm.2021.100789.; Wu F., Zhou Y., Wang Z., Xie M., Shi Z., Tang Z. et al. Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: A multicenter, retrospective, observational study. J. Thorac. Dis. 2020;12(5):1811–1823. DOI:10.21037/jtd-20-1914.; Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., Davidson K.W. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–2059. DOI:10.1001/jama.2020.6775.; Chhiba K.D., Patel G.B., Vu T.H.T., Chen M.M., Guo A., Kudlaty E. et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin. Immunol. 2020;146(2):307–314.e4. DOI:10.1016/j.jaci.2020.06.010.; Liu S., Cao Y., Du T., Zhi Y. Prevalence of Comorbid Asthma and Related Outcomes in COVID-19: A Systematic Review and Meta-Analysis. J. Allergy Clin. Immunol. Pract. 2021;9(2):693–701. DOI:10.1016/j.jaip.2020.11.054.; Luo J., Chen Y.L., Chen W., Duncan D.A., Hussain H., Sohail B. et al. Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19. Allergy Asthma Clin. Immunol. 2021;17(1):67. DOI:10.1186/s13223-021-00569-8.; Beurnier A., Jutant E.M., Jevnikar M., Boucly A., Pichon J., Preda M. et al. Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. Eur. Respir. J. 2020;56(5):2001875. DOI:10.1183/13993003.01875-2020.; Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q. et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. Int. J. Infect. Dis. 2020;94:91–95. DOI:10.1016/j.ijid.2020.03.017.; Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054–1062. DOI:10.1016/S0140-6736(20)30566-3.; Müllerova H., Agusti A., Erqou S., Mapel D.W. Cardiovascular comorbidity in COPD: Systematic literature review. Chest. 2013;144(4):1163– 1178. DOI:10.1378/chest.12-2847.; Lee H.M., Truong S.T., Wong N.D. Association of adult-onset asthma with specific cardiovascular conditions. Respir. Med. 2012;106(7):948– 953. DOI:10.1016/j.rmed.2012.02.017.; Matsushita K., Ding N., Kou M., Hu X., Zhang L., Huo P. et al. The Relationship of COVID-19 Severity with Cardiovascular Disease and Its Traditional Risk Factors: A Systematic Review and Meta-Analysis. Glob. Heart. 2020;15(1):64. DOI:10.5334/gh.814.; Jacobs M., Van Eeckhoutte H.P., Wijnant S.R.A., Janssens W., Joos G.F., Brusselle G.G. et al. Increased expression of ACE2, the SARSCoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects. Eur. Respir. J. 2020;56(2):2002378. DOI:10.1183/13993003.02378-2020.; Peters M.C., Sajuthi S., Deford P., Christenson S., Rios C.L., Montgomery M.T. et al. COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. Am. J. Respir. Crit. Care Med. 2020;202(1):83–90. DOI:10.1164/rccm.202003-0821OC.; Dahan S., Segal G., Katz I., Hellou T., Tietel M., Bryk G. et al. Ferritin as a marker of severity in COVID-19 patients: A fatal correlation. Isr. Med. Assoc. J. 2020;22(8):494–500.; https://www.sibjcem.ru/jour/article/view/1621Test

  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية
  6. 6
    دورية أكاديمية

    المصدر: Pharmacogenetics and Pharmacogenomics; № 1 (2021); 38-41 ; Фармакогенетика и фармакогеномика; № 1 (2021); 38-41 ; 2588-0527 ; 2686-8849

    وصف الملف: application/pdf

    العلاقة: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/219/214Test; Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018;9(2):e00221-18. DOI:10.1128/mBio.00221-18.; Siegel D, Hui HC, Doerffler E, et al. Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J Med Chem. 2017;60(5):1648–1661. DOI:10.1021/acs.jmedchem.6b01594.; Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. DOI:10.1038/s41422-020-0282-0.; Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383(19):1813–1826. DOI:10.1056/NEJMoa2007764.; Consortium WHOST, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):497–511. DOI:10.1056/NEJMoa2023184.; Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. September 2021:S1473-3099(21)00485-0. DOI:10.1016/S1473-3099(21)00485-0.; Mozaffari E, Chandak A, Zhang Z, et al. Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort. Clin Infect Dis. 2021 Oct 1;ciab875. DOI:10.1093/cid/ciab875.; Deb S, Reeves AA, Hopefl R, Bejusca R. ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential. Pharmaceuticals (Basel). 2021;14(7):655. DOI:10.3390/ph14070655.; Eastman RT, Roth JS, Brimacombe KR, et al. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Cent Sci. 2020;6(5):672–683. DOI:10.1021/acscentsci.0c00489.; Deb S, Reeves AA. Simulation of remdesivir disposition and its drug interactions. J Pharm Pharm Sci. 2021;24:277–291. DOI:10.18433/jpps32011.; Zhu H-J, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS. Carboxylesterase 1 as a Determinant of Clopidogrel Metabolism and Activation. J Pharmacol Exp Ther. 2013;344(3):665–672. DOI:10.1124/jpet.112.201640.; Shi J, Wang X, Nguyen JH, et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol. 2016;119:76–84. DOI:10.1016/j.bcp.2016.09.003.; Uesugi M, Hosokawa M, Shinke H, et al. Influence of Cytochrome P450 (CYP) 3A4*1G Polymorphism on the Pharmacokinetics of Tacrolimus, Probability of Acute Cellular Rejection, and mRNA Expression Level of CYP3A5 Rather than CYP3A4 in Living-Donor Liver Transplant Patients. Biol Pharm Bull. 2013;36(11):1814–1821. DOI:10.1248/bpb.b13-00509.; Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37–44. DOI:10.1002/cpt.597.; Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015;98(2):127–134. DOI:10.1002/cpt.147.; Ramsey LB, Johnson SG, Caudle KE, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. Clin Pharmacol Ther. 2014;96(4):423–428. DOI:10.1038/clpt.2014.125.; Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):489. DOI:10.1186/s12879-021-06164-x.; Lou Y, Liu L, Yao H, et al. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial. Eur J Pharm Sci. 2021;157:105631. DOI:10.1016/j.ejps.2020.105631.; Mishima E, Anzai N, Miyazaki M, Abe T. Uric Acid Elevation by Favipiravir, an Antiviral Drug. Tohoku J Exp Med. 2020;251(2):87–90. DOI:10.1620/tjem.251.87.; Takahashi H, Iwasaki Y, Watanabe T, et al. Case studies of SARSCoV- 2 treated with favipiravir among patients in critical or severe condition. Int J Infect Dis. 2020;100:283–285. DOI:10.1016/J.IJID.2020.08.047.; Murai Y, Kawasuji H, Takegoshi Y, et al. A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test. Int J Infect Dis. 2021;106:33–35. DOI:10.1016/J.IJID.2021.03.048.; Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020;209:107512. DOI:10.1016/j.pharmthera.2020.107512.; Madelain V, Nguyen THT, Olivo A, et al. Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. Clin Pharmacokinet. 2016;55(8):907–923. DOI:10.1007/s40262-015-0364-1.; Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, Patil S, Barkate H. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021 Jan;102:501-508. DOI:10.1016/j.ijid.2020.10.069.; Smith MA, Marinaki AM, Arenas M, et al. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment Pharmacol Ther. 2009;30(4):375–384. DOI:10.1111/ J.1365-2036.2009.04057.X.; Beedham C. Aldehyde oxidase; new approaches to old problems. Xenobiotica. 2020;50(1):34–50. DOI:10.1080/00498254.2019.1626029.; Stavropoulou E, Pircalabioru GG, Bezirtzoglou E. The Role of Cytochromes P450 in Infection. Front Immunol. 2018;9:89. DOI:10.3389/fimmu.2018.00089.; Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85(4):434–438. DOI:10.1038/clpt.2008.302.; Chakraborty C, Sharma AR, Bhattacharya M, Sharma G, Lee S-S, Agoramoorthy G. COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients. J Med Virol. 2020;92(11):2260–2262. DOI:10.1002/jmv.26078.; Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 2007;35(9):1687–1693. DOI:10.1124/dmd.107.015511.; Jover R, Bort R, Gómez-Lechón MJ, Castell J V. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J. 2002;16(13):1799–1801. DOI:10.1096/fj.02-0195fje.; Strafella C, Caputo V, Termine A, et al. Investigation of Genetic Variations of IL6 and IL6R as Potential Prognostic and Pharmacogenetics Biomarkers: Implications for COVID-19 and Neuroinflammatory Disorders. Life (Basel, Switzerland). 2020;10(12):351. DOI:10.3390/life10120351.; https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/219Test

  7. 7
    دورية أكاديمية
  8. 8
    مؤتمر

    وصف الملف: application/pdf

    العلاقة: Проблемы качества физкультурно-оздоровительной и здоровьесберегающей деятельности образовательных организаций : сборник материалов 11-й Всероссийской научно-практической конференции. - 2021; Могутова, М. С. Проблема обеспечения эффективности здоровьесберегающей деятельности в образовательных учреждениях в период пандемии / М. С. Могутова, К. Н. Бараковских // Проблемы качества физкультурно-оздоровительной и здоровьесберегающей деятельности образовательных организаций : сборник материалов 11-й Всероссийской научно-практической конференции с международным участием, 21 апреля 2021 г., г. Екатеринбург / Рос. гос. проф.-пед. ун-т. - Екатеринбург : РГППУ, 2021. - С. 75-80.; https://elar.rsvpu.ru/handle/123456789/36349Test

  9. 9
    دورية أكاديمية

    المصدر: Сборник статей

    وصف الملف: application/pdf

    العلاقة: Актуальные вопросы современной медицинской науки и здравоохранения: Материалы VI Международной научно-практической конференции молодых учёных и студентов, посвященной году науки и технологий, (Екатеринбург, 8-9 апреля 2021): в 3-х т.; Измоденова, В. А. Сравнение тест-систем для определения антител IgG к SARS-CoV-2 / В. А. Измоденова, Л. И. Савельев // Актуальные вопросы современной медицинской науки и здравоохранения: материалы VI Международной научно-практической конференции молодых учёных и студентов, посвященной году науки и технологий, (Екатеринбург, 8-9 апреля 2021 г.) : в 3-х т. – Екатеринбург : УГМУ, 2021. – Т.1. – с. 1568-1572.; http://elib.usma.ru/handle/usma/6902Test

  10. 10
    دورية أكاديمية

    المصدر: Mother and Baby in Kuzbass; № 1 (2021): март; 102-107 ; Мать и Дитя в Кузбассе; № 1 (2021): март; 102-107 ; 2542-0968 ; 1991-010X

    وصف الملف: text/html; application/pdf